Conventional antidepressants are widely employed in several psychiatric and neurologic
disorders, yet the mechanisms underlying their delayed and partial therapeutic effects are …

Depressive disorder is a complex, heterogeneous disease that affects approximately 280
million people worldwide. Environmental, genetic, and neurobiological factors contribute to …

Epigenetic modifications are plausible molecular sources of phenotypic heterogeneity
across schizophrenia patients. The current study investigated biological heterogeneity in …

Since the onset of the COVID-19 pandemic, increasing cases with variable outcomes
continue globally because of variants and despite vaccines and therapies. There is a need …

The Nod-like receptor pyrin containing 3 (NLRP3) inflammasome has been reported to be a
convergent point linking the peripheral immune response induced by psychological stress …

Background Despite significant advances in the understanding and treatment of obsessive
compulsive disorder (OCD), current treatment options are limited in terms of efficacy for …

Background Transcriptome studies have revealed age-, disease-, and region-associated
microglial phenotypes reflecting changes in microglial function during development, aging …

Simple Summary Anti-cancer drug response prediction models aim to reduce the time
necessary for developing a treatment for patients affected by this complex disease. Their …

Major depressive disorder (MDD) is one of the leading causes of disability worldwide.
Polymorphisms in cytochrome P450 genes (CYP450) were demonstrated to play a …

Aim: To identify the DNA methylation status of related genes in major depressive disorder
following selective serotonin-reuptake inhibitor treatment. Materials & methods: 45 patients …